BioCentury
ARTICLE | Finance

Ebb & Flow

March 16, 2009 7:00 AM UTC

Companies from across the development spectrum closed private rounds last week, with the amounts raised largely illustrative of how far up or downstream each company finds itself. On one end was Victory Pharma, a specialty pharma play that pulled in $45 million based on the strength of its portfolio of marketed pain products, while newco Igenica raised $6.2 million to begin validating its approach to cancer antibody discovery and development.

In between, mid-stage drug developers Relypsa and Surface Logix raised $10 million and $15 million dollops of cash respectively to advance lead programs in Phase II testing...